Pall: Quarterly set-backs but hurricanes fail to blow single-use off course

By Dan Stanton

- Last updated on GMT


Related tags Puerto rico

Pall Corporation suffered a significant impact in the third quarter after hurricanes shut down facilities in Puerto Rico and Florida.

Since buying Pall in 2015​, Danaher Corporation no longer publishes specific figures for individual business unit. However, in a conference call last week, Danaher CEO Thomas Joyce said Pall saw core growth decline over the quarter “primarily due to the negative impact of the recent hurricanes in Florida and Puerto Rico.”

Hurricane Irma hit Florida in September, partially affecting Pall’s fluid dynamic and aeropower businesses, but Hurricane Maria’s devastation of Puerto Rico had a significant impact on Pall’s life sciences Fajardo facility on the island.

The hurricane impact was significant. We were shut down for two weeks in Puerto Rico,”​ Joyce told investors. The facility has since

“While the recovery has been a challenging one, we expect to get some of that production recovered in the fourth quarter, probably not all of it. Some of it will extend probably into the first quarter.”

Despite the supply issues, the firm remains confident about the strength of its life sciences division, which has seen mid-single-digit order growth over the past six months. Its bioprocessing business – comprising mostly of single-use equipment and technology – specifically is faring even better, seeing double-digit growth in sales and orders for the quarter.

“[While] we obviously saw the related softness on the shipment side that was associated with the hurricane impact… the order growth that we mentioned and you heard us talk about gives us great encouragement that we're going to see a meaningful acceleration in the top-line associated with biopharma in the fourth quarter.”

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more